A Phase-2 Study of Nivolumab and Ipilimumab Combination, Ipilimumab alone or Cabazitaxel in Men with metastatic, castration-resistant Prostate Cancer (Check Mate-650) - AP 110/20 of AUO Second/Third-Line Therapy after Failure of Docetaxel in Patients with metastatic Prostate Cancer (mCRPC )

被引：0
|
作者：
Rexer, Heidrun [1 ]
Grimm, Marc-Oliver [2 ]
Boegemann, Martin [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Univ Klinikum Jena, Klin & Poliklin Urol, Leiter Klin Prufung, Klinikum 1, D-07747 Jena, Germany
[3] Deutsch Krebsgesell eV, Organgrp Sprecher Arbeitsgemeinschaft Urol, Kuno Fischer Str 8, D-14057 Berlin, Germany
来源：
AKTUELLE UROLOGIE | 2021年 / 52卷 / 04期
关键词：
D O I：
10.1055/a-1469-0239
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：316 / 317
页数：2
相关论文
共 50 条
  • [21] LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Hauke, Ralph J.
    Call, Justin A.
    Sun, Jichao
    Casey, Denise
    Wei, Xiao X.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS242 - TPS242
  • [22] Second-line Therapy for metastatic castration-resistant Prostate Cancer (mCRPC) A Phase III Randomized, Open-Label, Controlled Trial of Cabozantinib (XL184) in Combination with Atezolizumab vs. Second Novel Hormone Therapy (NHT) in Patients with Metastatic Castration-Resistant Prostate Cancer (CONTACT-02) - AUO Study AP 120/22
    Rexer, H.
    Merseburger, A.
    Hammerer, P.
    UROLOGIE, 2022, 61 (11): : 1305 - 1306
  • [23] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gulley, James L.
    Madan, Ravi A.
    Tsang, Kwong Y.
    Jochems, Caroline
    Dahut, William L.
    Schlom, Jeffrey
    CANCER RESEARCH, 2013, 73
  • [24] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Mohebtash, M.
    Madan, R. A.
    Arlen, P. M.
    Rauckhorst, M.
    Tsang, K. Y.
    Cereda, V.
    Vergati, M.
    Poole, D. J.
    Dahut, W. L.
    Schlom, J.
    Gulley, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
    Mateo, Joaquin
    Fizazi, Karim
    Pezaro, Carmel Jo
    Loriot, Yohann
    Mehra, Niven
    Albiges, Laurence
    Bianchini, Diletta
    Varga, Andrea
    Ryan, Charles J.
    Petrylak, Daniel Peter
    Shen, Liji
    Zhang, Jenny
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [26] TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Giannakakou, Paraskevi
    Kirby, Brian J.
    Nicacio, Leonardo V.
    Eisenberger, Mario A.
    Nanus, David M.
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).
    Boudadi, Karim
    Suzman, Daniel L.
    Luber, Brandon
    Wang, Hao
    Silberstein, John L.
    Taylor, Maritza N.
    Sullivan, Rana
    Dowling, Donna
    Harb, Rana
    Dittamore, Ryan Vance
    Meeker, Alan
    Luo, Jun
    Drake, Charles G.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [29] A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.
    Buonerba, Carlo
    Bosso, Davide
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [30] First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel
    Oudard, Stephane
    Sengelov, Lisa
    Mainwaring, Paul N.
    Thiery-Vuillemin, Antoine
    Theodore, Christine
    Kulikov, Evgeny
    Yachnin, Jeffrey
    Kocak, Ivo
    Kataja, Vesa V.
    Luukkaa, Marjaana
    Nosov, Aleander
    Hjelm-Eriksson, Marie
    Bubis, Jeffrey
    Shen, Liji
    Risse, Marie-Laure
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345